These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981 [TBL] [Abstract][Full Text] [Related]
10. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Trojaniello C; Festino L; Vanella V; Ascierto PA Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516 [TBL] [Abstract][Full Text] [Related]
11. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871 [TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
14. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. Trouiller JB; Macabeo B; Poll A; Howard D; Buckland A; Sivignon M; Clay E; Malka D; Samalin E; Toumi M; Laramée P BMJ Open; 2022 Nov; 12(11):e063700. PubMed ID: 36410812 [TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Pan YL Cancer Manag Res; 2018; 10():2289-2301. PubMed ID: 30122982 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. Indini A; Mandalà M Expert Opin Drug Saf; 2020 Oct; 19(10):1229-1236. PubMed ID: 32857940 [TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells. Lim SH; Lee SY; Hong JY; Lee J; Kim ST Transl Cancer Res; 2024 Jul; 13(7):3695-3703. PubMed ID: 39145064 [TBL] [Abstract][Full Text] [Related]
19. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma. Niessner H; Hüsch A; Kosnopfel C; Meinhardt M; Westphal D; Meier F; Schilling B; Sinnberg T Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067230 [TBL] [Abstract][Full Text] [Related]
20. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]